Q4 2024 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2025-02-14 · accession 0001636587-25-000009
$185.0M
Reported value
20
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $32.5M | 17.5% | 1,131,501 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $22.4M | 12.1% | 2,861,825 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $16.8M | 9.10% | 1,939,644 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $16.1M | 8.73% | 1,516,303 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $12.0M | 6.49% | 2,450,711 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $11.2M | 6.06% | 643,381 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $10.9M | 5.90% | 1,971,264 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $10.2M | 5.54% | 1,439,674 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $8.2M | 4.46% | 2,001,048 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $6.8M | 3.65% | 1,279,800 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $6.5M | 3.50% | 734,393 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $6.3M | 3.38% | 1,442,308 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $5.4M | 2.90% | 7,310,650 | Common | SOLE |
| G63365103 | MURA | MURAL ONCOLOGY PLC | $4.1M | 2.24% | 1,286,079 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCE INC | $3.6M | 1.96% | 1,147,052 | Common | SOLE |
| 68404V209 | OPTNUSD | OPTINOSE INC | $2.8M | 1.53% | 422,813 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $2.8M | 1.49% | 803,425 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $2.4M | 1.32% | 405,237 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $2.4M | 1.29% | 4,032,046 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $1.5M | 0.83% | 456,970 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.